03/06/2014

Significato prognostico dei linfociti tumore-infiltranti nel carcinoma mammario

"We and others have previously shown that an immune signal can influence prognosis and response to treatment, particularly “immunogenic therapies” in specific breast cancer subtypes, such as those estrogen receptor (ER)-negative and/or overexpressing the HER2/neu oncogene. To validate this further and determine immunity could be a clinically relevant biomarker, we evaluated the association between quantity of tumor infiltrating lymphocytes (TILs) in a breast cancer, prognosis and prediction of response to anthracyline chemotherapy in a large clinical trial in over 2000 primary breast cancers and long term follow-up data. We found that TILs were strongly associated with a good prognosis in the triple negative breast cancer (TNBC: ER, PGR, and HER2-negative) subtype)".
(Commentary on:  Loi S et al.: "Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98", J Clin Oncol. 2013 Jan 22. [Epub ahead of print]
)

Condividi
Altri articoli

Complicanze post-chirurgiche nelle pazienti operate per carcinoma mammario e aspetti riabilitativi

Condividi

Alterazioni del ritmo circadiano e rischio di carcinoma mammario

Condividi

Cadmio e rischio di neoplasia mammaria

Condividi

Radioterapia con protoni in donne affette da neoplasia mammaria

Condividi

L'antiepilettico fenitoina riduce la crescita cellulare e le metastasi del tumore mammario

Condividi